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Background: DNA methylation is a key epigenetic mechanism for driving and stabilizing cell-fate decisions. Local
deposition and removal of DNA methylation are tightly coupled with transcription factor binding, although the
relationship varies with the specific differentiation process. Conversion of monocytes to osteoclasts is a unique
terminal differentiation process within the hematopoietic system. This differentiation model is relevant to
autoimmune disease and cancer, and there is abundant knowledge on the sets of transcription factors involved.
Results: Here we focused on DNA methylation changes during osteoclastogenesis. Hypermethylation and
hypomethylation changes took place in several thousand genes, including all relevant osteoclast differentiation and
function categories. Hypomethylation occurred in association with changes in 5-hydroxymethylcytosine, a proposed
intermediate toward demethylation. Transcription factor binding motif analysis revealed an over-representation of
PU.1, NF-κB, and AP-1 (Jun/Fos) binding motifs in genes undergoing DNA methylation changes. Among these, only
PU.1 motifs were significantly enriched in both hypermethylated and hypomethylated genes; ChIP-seq data analysis
confirmed its association to both gene sets. Moreover, PU.1 interacts with both DNMT3b and TET2, suggesting its
participation in driving hypermethylation and hydroxymethylation-mediated hypomethylation. Consistent with this,
siRNA-mediated PU.1 knockdown in primary monocytes impaired the acquisition of DNA methylation and
expression changes, and reduced the association of TET2 and DNMT3b at PU.1 targets during osteoclast
differentiation.
Conclusions: The work described here identifies key changes in DNA methylation during monocyte-to-osteoclast
differentiation and reveals novel roles for PU.1 in this process.Background
DNA methylation plays a fundamental role in differenti-
ation as it drives and stabilizes gene activity states during
cell-fate decisions. Recent reports have shown a close re-
lationship between the participation of transcription fac-
tors during differentiation and the generation of cell
type-specific epigenetic signatures [1-3]. Several mecha-
nisms explain the co-occurrence of DNA methylation* Correspondence: eballestar@idibell.org
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reproduction in any medium, provided the orchanges and transcription factor binding, including the
active recruitment of enzymes involved in DNA methy-
lation deposition, interference, or alternative use of the
same genomic regions. One of the best models for
investigating these mechanisms is the hematopoietic dif-
ferentiation system given the profound knowledge on
the transcription factors implicated at different stages.
Many studies have focused on hematopoiesis in order to
learn about the type, distribution, and role of epigenetic
changes, particularly DNA methylation during differenti-
ation. However, the role of DNA methylation changes
and the mechanisms participating in their acquisition in
terminal differentiation processes remain elusive, evenral Ltd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly cited.
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produce functional cell types with very specific roles.
A singular differentiation process within the hemato-
poietic system is represented by differentiation from
monocytes (MOs) to osteoclasts (OCs), which are giant,
multinucleated cells that are specialized in degrading
bone [4]. OCs differentiate from monocyte/macrophage
progenitors following M-CSF [5] and RANKL [6]
stimulation. Osteoclastogenesis requires cell fusion,
cytoskeleton re-organization [7] and the activation of the
specific gene sets necessary for bone catabolism. The
signaling pathways activated after M-CSF and RANKL
induction have been extensively described, and act
through TRAF-6 [8,9], immunoreceptor tyrosine-based
activation motif (ITAM) [10] adaptors DAP12 [11] and
FcRγ [12] associated with their respective receptors,
TREM-2 [13] and OSCAR, as well as calcium oscilla-
tions [14]. Signals end in the activation of NF-kB,
MAPK, and c-Jun, leading to the activation of NFATc1
[15], the master transcription factor of osteoclasto-
genesis, together with PU.1 and MITF [16], which is
already present in the progenitors. These transcription
factors bind to the promoter and help upregulating OC
markers such as dendritic cell-specific transmembrane
protein (DC-STAMP/TM7SF4) [17], tartrate-resistant
acid phosphatase (TRACP/ACP5) [18], cathepsin K
(CTSK) [19], matrix metalloproteinase 9 (MMP9) [20],
and carbonic anhydrase 2 (CA2).
OC deregulation is involved in several pathological
contexts, either in the form of deficient function, as in
the case in osteopetrosis [21], or aberrant hyperacti-
vation, as in osteoporosis [22]. These cells are also in-
volved in autoimmune rheumatic disease. For instance,
in rheumatoid arthritis aberrantly activated OCs are
major effectors of joint destruction [23]. Moreover, OCs
cause bone complications in several diseases, such as
multiple myeloma [24], prostate cancer, and breast can-
cer [25], and there is also a specific tumor with OC ori-
gin, the giant cell tumor of bone [26].
In vitro generation of OCs allows this cell type to be
investigated, whereas isolating primary bone OCs for
this purpose is very difficult. MOs stimulated with
RANKL and M-CSF generate functional OCs [27], which
degrade bone and express OC markers [28]. As indi-
cated, the involvement of transcription factors in this
model has been well studied, however very few reports
have analyzed the role of epigenetic changes during
osteoclastogenesis, and these focus mainly on histone
modifications [29,30]. Given the relationship between
transcription factors and DNA methylation, we hypothe-
sized that examining DNA methylation changes would
provide clues about the involvement of specific factors
in the dynamics and hierarchy of these changes in ter-
minal differentiation.In this study, we compared the DNA methylation pro-
files of MOs and derived OCs following M-CSF and
RANKL stimulation. We found that osteoclastogenesis
was associated with the drastic reshaping of the DNA
methylation landscape. Hypermethylation and hypome-
thylation occur in many relevant functional categories
and key genes, including those whose functions are cru-
cial to OC biology, like CTSK, ACP5, and DC-STAMP.
Hypomethylation occurred early, concomitantly with
transcription changes, was DNA replication-independent
and associated with a change in 5-hydroxymethy-
lcytosine, which has been proposed as an intermediate
in the process of demethylation. Inspection of transcrip-
tion factor binding motif over-representation in genes
undergoing DNA methylation changes revealed the en-
richment of the PU.1 binding motif in hypermethylated
genes and AP-1, NF-kB, and also PU.1 motifs among
hypomethylated genes. In fact, analysis of PU.1 ChIPseq
data showed its general association to a high number of
both hypo- and hypermethylated sites. Chromatin im-
munoprecipitation assays and immunoprecipitation ex-
periments suggested a potential novel role for PU.1
recruiting DNMT3B to hypermethylated promoters, and
TET2, which converts 5-methylcytosine to 5-hydroxy-
methylcytosine, to genes that become demethylated.
This has been demonstrated by performing siRNA-
mediated downregulation of PU.1 which partially im-
paired DNA methylation, expression, and recruitment of
TET2 and DNMT3B to PU.1 targets, supporting the par-
ticipation of PU.1 in the acquisition of DNA methylation
changes at their target sites.
Results
Cell differentiation and fusion in osteoclastogenesis are
accompanied by hypomethylation and hypermethylation
of key functional pathways and genes
To investigate the acquisition of DNA methylation
changes during monocyte-to-osteoclast differentiation
we first obtained three sets of matching samples corre-
sponding to MOs (CD14+ cells) from peripheral blood
and OCs derived from the same CD14+ cells, 21 days
after the addition of M-CSF and RANKL. The quality of
mature, bone-resorbing OCs obtained under these con-
ditions was confirmed by several methods, including the
presence of more than three nuclei in TRAP-positive
cells (in some cases, up to 40 nuclei per cell were
counted), the upregulation of OC markers, such as CA2,
CTSK, ACP5/TRACP, and MMP9, and downregulation
of the monocytic gene CX3CR1 (Additional file 1). At
21 days, over 84% of the nuclei detected in these prepa-
rations could be considered to be osteoclastic nuclei
(in polykaryons, nuclei and not cells were counted)
(Additional file 1). We then performed DNA methyla-
tion profiling using bead arrays that interrogate the
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the entire genome covering 99% of RefSeq genes. Statis-
tical analysis of the combined data from the three pairs
of samples revealed that 3,515 genes (8,028 CpGs)
displayed differential methylation (FC ≥2 or FC ≤0.5;
false discovery rate (FDR) ≤0.05). Specifically, we identi-
fied 1,895 hypomethylated genes (3,597 CpG sites) and
2,054 hypermethylated genes (4,429 CpGs) (Figure 1A
and Additional file 2). Changes corresponding to the
average three pairs of monocytes/osteoclasts (Figure 1B)
were almost identical to the pattern obtained for each
individual pair of samples (Additional file 3), highlight-
ing the specificity of the differences observed.
Over one-third of the differentially methylated CpG-
containing probes (33% for hypomethylated CpGs, 45%
for hypermethylated CpGs) mapped to gene promoters,
the best-described regulatory region for DNA methyla-
tion, although DNA methylation changes also occurred
at a similar scale in gene bodies (51% for hypo-
methylated CpGs, 40% for hypermethylated CpGs)
(Figure 1C). Gene ontology analysis of hypomethylated
CpGs revealed significant enrichment (FDR ≤0.05) for a
variety of functional categories of relevance in OC differ-
entiation and function (Figure 1D). We observed very
high significance for terms like immune response
(FDR = 4.25E-25) and signal transduction (FDR = 1.45E-
21), but also more specific categories such as ruffle
organization (FDR = 9.91E-2), calcium ion transport
(FDR = 4.6E-2), and OC differentiation (FDR = 1.94E-1).
In the case of hypermethylated genes, we also found
highly significant enrichment of signal transduction
(FDR = 4.09E-17), and enrichment of categories related
to other hematopoietic cell types, suggesting that
hypermethylation and associated silencing take place in
gene sets that become silent in differentiated OCs
(Figure 1D). Together, these data indicate that DNA
hypomethylation is targeted to genomic regions that are
activated during osteoclastogenesis, and hypermethy-
lation silences alternative lineage genes that are not
expressed in OCs.
Remarkably, among the group of hypomethylated
genes (Additional file 2), we identified changes in several
of the archetypal OC genes near their transcription start
sites. For example, CTSK, the lysosomal cysteine pro-
teinase involved in bone remodeling and resorption, is
hypomethylated more than 60%. The ACP5/TRACP gene
is hypomethylated around 47%. Finally, TM7SF4, which
encodes for DC-STAMP, a seven-pass transmembrane
protein involved in signal transduction in OCs and den-
dritic cells, undergoes 59% hypomethylation. We also
observed significant hypomethylation at the osteoclast-
specific transcription factor gene NFATC1, although in
this case hypomethylation occurred at CpG sites located
in its gene body region. Conversely, CX3CR1, animportant factor for MO adhesion to blood vessels that
is downregulated during osteoclastogenesis, displayed an
increase in methylation of over 28% (Additional file 2).
To confirm that differences in DNA methylation iden-
tified between MOs and OCs were robust, we carried
out bisulfite genomic pyrosequencing of the aforemen-
tioned selection of genes, looking at CpG sites corre-
sponding to the oligonucleotide probe represented in
the methylation array. In all cases, bisulfite pyrose-
quencing confirmed the results of the beadchip array
(Figure 1E and Additional file 4). This analysis showed
a very close correlation between the array and the
pyrosequencing data (R2 = 0.9707) (Figure 1E).
We also investigated the coordinated hypomethylation
or hypermethylation of adjacent CpGs by analyzing the
different sequence window lengths (from 500 bp to
1,000,000 bp). With the largest sequence windows we
were able to observe the coordinated hypermethylation
of multiple CpGs across several genes, like those in the
HOXA gene cluster. However, the majority of CpGs
undergoing coordinated methylation changes were iden-
tified within the single gene level. By analyzing CpGs
that are concomitantly deregulated within a 500-bp win-
dow, we identified several genes displaying coordinated
hypomethylation or hypermethylation of many CpG sites
(Additional file 5). Among these, we identified several
CpG clusters in genes potentially involved in OC func-
tion and/or differentiation, including 10 CpGs at the
promoter of the TM4SF19 gene, also known as OC
maturation-associated gene 4 protein, and nine CpGs in
the gene body of ARID5B, the AT-rich interactive do-
main 5B (MRF1-like) (Figure 1F).
To examine the specificity of the DNA methylation
changes further we performed bisulfite sequencing of re-
petitive elements (Sat2, D4Z4, and NBL2 repeats) and ribo-
somal RNA genes (Figure 1G and Additional file 3). We
also performed genome-wide amplification of unmethylated
DNA Alu repeats (AUMA), the most common family of re-
petitive elements that are present in tandem or interspersed
in the genome [31]. These experiments showed no signifi-
cant DNA methylation changes in any of these repetitive el-
ements (Additional file 3), reinforcing the notion of the
high specificity of hypomethylation and hypermethylation
of the identified gene sets.
Hypomethylation is replication-independent and involves
changes in 5-hydroxymethylcytosine
To investigate the dynamics of DNA methylation in rela-
tion to gene expression changes we first examined how
DNA methylation changes are associated with expres-
sion changes and then compared the dynamics of DNA
methylation and expression changes.
We used osteoclastogenesis expression data (available
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Figure 1 High-throughput methylation comparison between monocytes (MOs) and derived osteoclasts (OCs). (A) Heatmap including the
data for three paired samples of MOs (MO D1, D2, D3) and their derived OCs (OC D1, D2, D3) harvested on day 21. The heatmap includes all
CpG-containing probes displaying significant methylation changes (8,028 in total with FC ≥2 or FC ≤0.5; P ≤0.01 and FDR ≤0.05) (Additional file
2). Scale shown at the bottom, whereby beta values (that is, the ratio of the methylated probe intensity to the overall intensity, where overall
intensity is the sum of methylated and unmethylated probe intensities) ranging from 0 (unmethylated, blue) to 1 (completely methylated, red).
(B) Scatterplot showing the mean methylation profile of three matching MO/OC pairs. Genes with significant differences (FC >2, FDR <0.05) in
averaged results from the three pairs of samples are highlighted in red (hypermethylated) or blue (hypomethylated). (C) Distribution of
differentially methylated CpGs among genomic regions (promoter, gene bodies, 3′UTR, and intergenic) in different subsets of CpGs
(hypomethylated, hypermethylated). (D) Gene ontology enrichment analysis of hypomethylated and hypermethylated CpGs showing the most
important categories. (E) Technical validation of the array data by bisulfite pyrosequencing of modified DNA. BS pyrosequencing of three
representative hypomethylated genes (ACP5, CTSK, and TM7SF4) and one hypermethylated gene (CX3CR1) from the array data are shown. A
representation showing the excellent correlation between array data (beta values) and pyrosequencing data (% methylation) including the data
for the four genes (right panel). (F) Cluster analysis of contiguous differentially methylated regions (<500 bp). Two examples of regions with more
than nine consecutive CpGs differentially methylated are shown. (G) Analysis of methylation levels in repetitive elements (Sat2, D4Z4, NBL2) and
ribosomal RNA genes (18S and 28S regions) as obtained from bisulfite sequencing analysis.
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Figure 2 (See legend on next page.)
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Figure 2 Dynamics of DNA methylation and its relationship with expression changes. (A) Heatmap showing expression levels on 0, 5, and
20 days for genes displaying significant methylation and expression changes (4,753 in total with FC ≥2 or FC ≤0.5; P ≤0.01 and FDR ≤0.05)
(Additional file 7). (B) Scatterplots showing the relationship between the log2-transformed FC in expression and the log2-transformed FC in DNA
methylation. Sixty-two percent of the hypomethylated genes are overexpressed (in blue); 55% of the hypermethylated genes are repressed (in
red). (C) Correlation between methylation and expression data (slope from the linear regression between DNA methylation differences versus
expression differences) for all differentially methylated genes organized by genomic location (first exon, TSS, 5′UTR, gene body, 3′UTR). (D) DNA
methylation and expression dynamics of selected loci during monocyte-to-osteoclast differentiation. Methylation percentage determined by
bisulfite pyrosequencing. Quantitative RT-PCR data relative to RPL38. DNA methylation and expression data are represented with a black line and
a red line, respectively. (E) BrdU assay showing the percentage of replicating cells at different times. From days 1 to 4, only 9.46% of cells divide.
(F) Effects of 5azadC treatment (50 nM, 500 nM) on osteoclastogenesis monitoring ACP5, CTSK, and CX3CR1 levels and TRAP staining over time.
(G) Workflow for testing the presence of 5 hydroxymethylcytosine in hypomethylated genes. DNA was treated with a 5hmC-specific
glucosyltransferase. Cytosines bearing a 5-hydroxymethyl are protected against MspI digestion, and the surrounding region can be amplified by
qPCR. When no 5hmC is present, glucose is not transferred to C, DNA is cleaved at CCGG sites, and there is less qPCR amplification. Several
controls are used to set the 0% and 100% content of 5hmC. (H) 5hmC content in several of the CpGs that are rapidly demethylated after RANKL
and M-CSF stimulation of OC precursors.
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showed that most changes occurred within the first
5 days, since the expression changes between 0 and
5 days were very similar to those observed between 0
and 20 days, and very few genes changed between 5 and
20 days (Figure 2A and Additional file 6). The 0-to-
20-day comparison showed that 2,895 genes were
upregulated (FC >2; FDR <0.05) and 1,858 were
downregulated (FC <0.5; FDR <0.05). We found different
relationships between DNA methylation changes and
gene expression (Figure 2B). An inverse relationship
between DNA methylation and gene expression was
mainly observed for changes occurring in CpGs in
the proximity of the TSS and within the first exon
(Figure 2C) and it was less frequent in those at gene
bodies and 3′UTR (Figure 2C). Comparing DNA methy-
lation and expression data revealed that 452 genes were
both hypomethylated and overexpressed and 280 genes
were both hypermethylated and repressed at the selected
thresholds (Additional file 7). We selected a panel of 10
genes from those undergoing hypomethylation and
hypermethylation to investigate the dynamics of DNA
methylation and expression changes, and performed bi-
sulfite pyrosequencing and quantitative RT-PCR over
the entire osteoclastogenesis for three sets of samples
(Figure 2D). We found that the promoters of genes like
ACP5, CTSK, TM7SF4, and TM4SF19 rapidly became
hypomethylated following RANKL and M-CSF stimula-
tion (Figure 2D, top). In fact, around 60% of the entire
range of hypomethylation occurred between days 0 and
4. Changes in mRNA levels occurred at a similar pace
or, in some cases, in an even more gradual manner and
were slightly delayed with respect to changes in DNA
methylation. In contrast, hypermethylated genes like
PPP1R16B, CD6, and NR4A2 (Figure 2D, bottom)
displayed loss of expression before experiencing an in-
crease in DNA methylation, highlighting the different
dynamics and mechanisms involved in hypomethylation
and hypermethylation events.It is well established that osteoclastogenesis occurs in
the absence of cell division. We tested the levels of cell
division in our monocyte-to-osteoclast differentiation
experiments by treating cells with BrdU pulses. Consist-
ent with previous observations, fewer than 9.8% were
found to be BrdU-positive between 1 and 4 days,
confirming the virtual absence of replication (Figure 2E
and Additional file 8). This implies that the large DNA
methylation changes observed in this time period are in-
dependent of DNA replication. This conclusion is also
supported by the fact that treatment with 5-Aza-2′-
deoxycytidine (5azadC), a pharmacological compound
that results in replication-coupled DNA demethylation
[33], had no significant effect on osteoclastogenesis
(Figure 2F).
The existence of DNA methylation changes in the ab-
sence of replication is particularly significant for genes
undergoing demethylation, given the controversy around
active DNA demethylation mechanisms. In this context,
recent studies have drawn attention towards a family of
enzymes, the Tet proteins, which convert 5-methy
lcytosine (5mC) to 5-hydroxymethylcytosine (5hmC)
[34,35] and other modified forms of cytosine,
5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)
[36]. 5hmC, 5fC, and 5caC may represent intermediates
in an active demethylation pathway that ultimately re-
places 5mC with cytosine in non-dividing cells [37,38].
To establish the potential involvement of these mecha-
nisms, we here focused on the 5hmC levels at early time
points in several of the genes that are hypomethylated
during osteoclastogenesis, using a method that cleaves
DNA that has C, 5mC, but not the glucosyl-5hmC pro-
duced as a result of treatment with the 5-hydroxymethy
lcytosine specific glucosyltransferase enzyme (Figure 2G).
For several genes that become hypomethylated, like
ACP5 and TM4SF19, we observed an initial increase in
5hmC levels followed by a slight but significant decrease
(Figure 2H). In other genes, like TM7SF4 and CD59, of
there were high levels of 5hmC before the addition of
HYPERMETHYLATED CpGsHYPOMETHYLATED CpGsA
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Figure 3 (See legend on next page.)
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Figure 3 Association of transcription factors with DNA methylation changes during moncoyte to OC differentiation. (A) Significant
enrichment of predicted TF (TRANSFAC motif) in hypo-/hypermethylated CpG sites regions. A 500-bp window centered around the
hypo-/hypermethylated CpG sites was tested. The name of the transcription factor binding motif, the P value and the TF family are provided.
Below we show three of the motifs that have a higher representation in this analysis. (B) Diagrams showing the percentage of hypo-/hyperme
thylated CpGs with AP-1, NF-kB, and PU.1 binding sites relative to the total number of hypo-/hypermethylated CpGs. (C) Quantitative ChIP assays
showing the binding of three selected transcription factors (p65 NF-kB subunit, Fos, and PU.1 to target genes selected by the presence of the
putative binding motifs according to the TRANSFAC analysis). Samples were analyzed at 0 and 2 days after RANKL/M-CSF stimulation. We used
Sat2 repeats and the TRDR1 MyoD1 promoter as negative control sequences.
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for demethylation. In any case, our results suggested the
participation of hydroxymethylation, and therefore the
activity of Tet proteins, in genes that undergo a reduc-
tion in DNA methylation.
Sequences undergoing DNA methylation changes are
enriched for binding motifs for AP-1, NF-kB, and PU.1,
key transcription factors in osteoclastogenesis
Different studies have recently shown that transcription
factor binding events are associated with changes in the
DNA methylation profiles and the response to different
situations [2,39,40]. To address this further, we first
investigated the potential over-representation of tran-
scription factor binding motifs among the sequences
undergoing DNA methylation changes during OC differ-
entiation using the TRANSFAC database and focusing
on a region of 500 bp around the CpG sites identified as
undergoing hypomethylation or hypermethylation. We
noted highly significant overrepresentation of a small
selection of transcription factor binding motifs for genes
that undergo hypomethylation or hypermethylation
(Figure 3A). We observed that the over-representation
of binding motifs was very specific to the direction of
the DNA methylation change (hypomethylation or
hypermethylation).
In the case of hypomethylated genes, we observed
highly significant enrichment of binding motifs of the
AP-1 family and NF-kB subunits (Figure 3A). We also
observed enrichment of PU.1 (FDR 1.07E-12). In fact,
39% of all hypomethylated genes had binding motifs for
AP-1, 15% genes had NF-kB binding motifs, and another
15% genes had binding motifs for PU.1 or other ETS-
related factors (PU.1 alone, 9%) (Figure 3B). As afore-
mentioned, these three groups of TFs play critical roles
in osteoclastogenesis [41]. For instance, c-Fos, a compo-
nent of the dimeric TF AP-1, regulate the switch be-
tween monocytes/macrophages and OC differentiation.
Fra-1 is downstream to c-Fos, whereas PU.1 and NF-kB
are upstream. NF-kB is critical in the expression of a
variety of cytokines involved in OC differentiation. In
the case of hypermethylated genes, we identified even
greater enrichment of the binding motifs of ETS-related
transcription factors, especially PU.1 (Figure 3A). In fact,the PU.1 binding motif is present in 15% of all
hypermethylated genes (Figure 3B). Other motifs of
ETS-related transcription factors from our list of
hypermethylated genes included SPIB, ESE1, ETS1,
ETS2, and others (Figure 3A). Much lower or insignifi-
cant levels of enrichment were obtained for AP-1 family
members and NF-kB subunits among the hyperme
thylated genes. Previous studies have shown that genes
that become methylated during hematopoietic differenti-
ation are characterized by ETS transcription factors [2].
This appears to be particularly relevant in monocytic dif-
ferentiation [1]. Interestingly, most of the reports about
the role of PU.1 in osteoclastogenesis are associated with
the activation of osteoclast-specific genes. However, in
relation with methylation changes, PU.1 appears to be
better correlated with those changes in the direction of
repression. Overall, the analysis of transcription factor
motifs showed that several of the factors associated with
osteoclastogenesis had a significant over-representation
of their binding motifs among the sets of hypo-and
hypermethylated genes (Additional file 9).
To confirm the association of some of these factors
with genes that become hypo- and hypermethylated we
performed chromatin immunoprecipitation (ChIP) as-
says with a selection of transcription factors including
PU.1, the NFkB subunit p65 and c-Fos, given their
known role in osteoclastogenesis as well as the presence
of binding motifs for them around hypo- and
hypermethylated genes (in the case of c-Fos, it was
chosen as a component of the dimeric TF AP-1). To se-
lect candidate genes we considered genes with motifs for
these three factors among the list of hypo- and
hypermethylated genes. For instance, genes that become
hypomethylated and have binding sites for p65 include
CCL5, IL1R, and TNFR5SF. In the case of transcription
factor c-Fos, we looked at genes that become
hypomethylated like IL7R, CD59, and IL1R. In the case
of PU.1, we chose key genes with PU.1 binding near the
differentially methylated CpG, including ACP5 and
TM4SF7 (hypomethylated) and CX3CR1 (hypermethy-
lated). ChIP assays demonstrated the interaction of these
factors with most of the aforementioned promoters,
even before the stimulation with M-CSF and RANKL
(Figure 3C), as if these genes were primed by these
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Figure 4 (See legend on next page.)
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Figure 4 Interactions between PU.1 and DNTM3b and TET2 and association with promoters undergoing DNA methylation changes. (A)
Quantitative RT-PCR analysis for CTSK, PU.1, p65 NF-kB, TET1, TET2, and DNMT3B during osteoclastogenesis. (B) Western blot for the same factors
indicated above. (C) Immunoprecipitation experiment of p65 and PU.1 with DNMT3B and TET2 at 0, 2, and 4 days after RANKL and M-CSF
stimulation. IgG used as a negative control. Reciprocal immunoprecipitation experiments in the bottom panel. (D) Quantitative ChIP assays
showing PU.1, TET2, and DNMT3b binding to hypomethylated genes (ACP5, TM7SF4, TM4SF19) and hypermethylated genes (CX3CR1, NR4A2), all
direct PU.1 targets, and a negative control (MYOD1 promoter) without PU.1 target sites. The experiment was performed with three biological
triplicates but only one experiment is shown. T-student test comparing binding of each antibody between 0 days vs. 2 days was performed: *
corresponds to P value <0.05; ** means P value <0.01; *** means P value <0.001. (E) Examples showing PU.1 binding (from ChIPseq data,
GSE31621) to the region neighboring hypo- and hypermethylated CpGs. The PU.1 binding motif location is presented as a horizontal blue dot
and the CpG displaying differential methylation (Illumina probe) between MO and OC is marked with a red bar. (F) Analysis of ChIPseq analysis
for PU.1 and comparison to TRANSFAC predictions. Top panel: proportion of the CpG-containing probes displaying DNA methylation changes
that have peaks for PU.1 binding in the same 500-bp window. Diagrams are separated in the hypo- and hypermethylated sets and in promoter
and distal regions (gene bodies, 3′UTR, and intergenic regions). Bottom panel, Venn diagrams showing the overlap of PU.1 targets from ChIPseq
data (GEO accession number: GSE31621) in MOs and TRANSFAC prediction for PU.1, both using a window of 500 pb centered by the CpG
displaying significant methylation changes.
de la Rica et al. Genome Biology 2013, 14:R99 Page 10 of 21
http://genomebiology.com/2013/14/9/R99factors in monocytes. No binding was observed in con-
trol sequences like Sat2 repeats and the MYOD1 and
TDRD1 promoters. Interestingly, in the case of PU.1,
with both hypo- and hypermethylated genes displaying
binding at 0 days, genes becoming demethylated showed
a slight increase in PU.1 binding, whereas hypermethy-
lated genes showed a slight decrease in PU.1 association
(Figure 3C).
PU.1 recruits DNMT3b and TET2 to hypermethylated and
hypomethylated genes
To investigate the potential role of the aforementioned
transcription factors in the acquisition of DNA methyla-
tion changes we chose PU.1 and NF-kB (p65 subunit) as
two representative examples. We first checked their ex-
pression levels during osteoclastogenesis, by carrying out
qRT-PCR and western blot assays. mRNA and protein
analysis (Figure 4A and 4B) both confirmed the expres-
sion of these factors. PU.1 revealed an increase at the
mRNA levels, although there was no change at the pro-
tein level. In the case of p65 NF-kB we only observed a
clear increase at the protein level (Figure 4B). In parallel,
we also confirmed the presence of DNMT3b, a de novo
DNA methyltransferase, and the ten eleven translocation
(TET) protein TET2, as enzymatic activities potentially
related with DNA demethylation (Figure 4A and 4B).
TET proteins are responsible for conversion of 5mC in
5hmC [34], 5fC, and 5cac [36]. Recent evidences support
a role for TET-dependent active DNA demethylation
process [42,43]. We focused on TET2 given their high
levels in hematopoietic cells of myeloid origin [44,45].
Also, we have recently reported that TET2 plays a role
in derepressing genes in pre-B cell to macrophage differ-
entiation [44], and recent data shows that TET2 is re-
quired for active DNA demethylation in primary human
MOs [45]. In fact TET1 and TET3 were undetectable in
western blot (not shown) and qRT-PCR evidenced their
low levels in this cell type (Figure 4A, only shown for
TET1).The confirmed binding of factors like PU.1 and the
p65 subunit of NF-kB to hypo- and hypermethylated
genes (Figure 3C) raised the possibility of their potential
direct interaction with factors involved in maintaining
the DNA methylation homeostasis. Some of these inter-
actions have already been explored. For instance, PU.1
physically interacts with the de novo DNA methyl-
transferases DNMT3A and DNMT3B [46]. Such an
interaction, if it occurred in osteoclastogenesis, could
provide a potential mechanism to explain how PU.1 tar-
get genes become hypermethylated. One would expect
that these transcription factors could also interact with
factors participating in demethylation processes. Our
previous results suggested the existence of 5hmC enrich-
ment in genes that become hypomethylated, and there-
fore it is reasonable to test whether NF-kB p65 and PU.1
interact with Tet proteins, the enzymes catalyzing hy-
droxylation of 5mC.
We therefore tested the recruitment by NF-kB p65
and PU.1 of both DNMT3b and TET2 by carrying
out immunoprecipitation assays with osteoclastogenesis
samples 0, 2, and 4 days after stimulation with M-CSF
and RANKL. Our results showed that PU.1 directly
interacted with both DNMT3b and TET2 (Figure 4C). It
is plausible that these two interactions may involve dif-
ferent subpopulations of PU.1, for instance with specific
post-translational modifications like Ser phosphoryl-
ation. However, we did not address this aspect at this
point. In the case of NF-kB, we did not observe binding
with either of these factors (Figure 4C). This could per-
haps be explained by the fact that p65 is shuttling back
to the cytoplasm much of the time.
To confirm the interaction between PU.1 and
DNMT3b and TET2, we performed reciprocal immuno-
prepitation experiments with anti-DNMT3b and anti-
TET2. These confirmed the direct interaction with PU.1
(Figure 4C). Our results suggested that PU.1 may play a
dual coupling transcription factor that can interact
with the DNA methyltransferases and enzymes perhaps
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that other factors participate in the recruitment of these
enzymes, however at this stage we focused on PU.1 be-
cause of its ability to bind both DNMT3b and Tet2 and
its association with both hyper- and hypomethylated
sequences.
We then investigated the dual role of PU.1 in
recruiting TET2 and DNMT3b to promoters. To this
end we performed chromatin immunoprecipitation as-
says with PU.1, TET2, and DNMT3b in MOs at 0 and
2 days following stimulation with M-CSF/RANKL. We
amplified gene promoters with predicted binding sites
for PU.1 that become both demethylated (ACP5,
TMS7SF4, and TM4SF19) as well as hypermethylated
(CX3CR1 and NR4A2) and used a non-target of PU.1
(MYOD1) as negative control. Our analysis showed
binding of PU.1 at both 0 and 2 days (Figure 4D). For
genes that become hypomethylated, we observed an in-
creased recruitment of TET2 at these promoters after
2 days, whereas DNMT3b was initially enriched but its
association with these promoters was lost after M-CSF
and RANKL stimulation (Figure 4D). In genes that be-
come hypermethylated (CX3CR1 and NR4A2), we also
observed association of PU.1 at both 0 and 2 days. How-
ever we again observed a slight decrease at 2 days to-
gether. We also observed increased recruitment of
DNMT3b at 2 days after M-CSF/ RANKL stimulation.
We did not observe association of PU.1, DNMT3b, and
TET2 in the negative control for PU.1 binding, the
MyoD promoter.
To evaluate the extent to which hypo- and hyper-
methylated genes correlate with PU.1 occupancy, we
used our DNA methylation data and PU.1 ChIPseq data
(GSE31621) obtained in MOs [1]. Most of the individual
example genes previously analyzed displayed PU.1 bind-
ing overlapping or in the proximity of the CpG sites
undergoing a methylation change (Figure 4E). To
systematize the analysis we used a window of 500 bp
centered around the CpG displaying DNA methylation
changes. Under these conditions we found that 10.7% of
all hypomethylated CpGs located in promoter regions
genes and 25.1% of all hypermethylated CpGs located in
promoter regions had PU.1 peaks within this 500-bp
window (Figure 4F). These numbers were similar when
focusing on CpGs located in distal regions (Figure 4F).
We also compared the ChIPseq data to the prediction by
TRANSFAC analysis and observed that the overlap
between the two sets of list was around 20.6% for
hypomethylated genes and 46.9% for hypermethylated
genes, again using the same 500 bp for both datasets
(Figure 4F). These analyses reinforced the notion of
PU.1 associated with a high number of genes undergoing
DNA methylation changes; however, it also reveals the
weakness in the predictive power of TRANSFAC motifsearches and the need of experimental validation of its
results.Dowregulation of PU.1 in MOs impairs activation of OC
markers, hypomethylation, and recruitment of DNMT3b
and TET2
To investigate a potential causal relationship between
PU.1 and DNA methylation changes in monocyte-
to-osteoclast differentiation we investigated the effects
of ablating PU.1 expression in MOs. We therefore
downregulated PU.1 levels in MOs using transient trans-
fection experiments with a mix of two siRNAs targeting
exon2 and the 3′UTR of PU.1 (Figure 5A). In parallel,
we used a control siRNA. Following transfection we
stimulated differentiation using RANKL/M-CSF. In
these conditions, we checked by qRT-PCR and western
blot the effects on PU.1 levels at 1, 2, 4, and 6 days fol-
lowing RANKL/M-CSF stimulation of MOs and con-
firmed the PU.1 downregulation close to 60% (Figure 5B
and 5C). We then observed that the upregulation of
genes like ACP5 and CTSK (both PU.1-direct targets)
was partially impaired (Figure 5D). In the case of genes
like CX3CR1 and NR4A2 we determined that downre-
gulation was also impaired in PU.1-siRNA treated MOs.
Interestingly, we also analyzed two genes that are not
direct PU.1 targets, one upregulated and hypomethylated
during osteoclastogenesis (PLA2G4E) and a second one,
highly methylated, that does not experience DNA
methylation changes during OC differentiation (FSCN3).
PU.1-siRNA treatment had only small effects on gene
expression changes during osteoclast differentiation
(perhaps due to indirect effects) when compared to con-
trol siRNA, confirming the specificity of the changes ob-
served for the other genes (Figure 5D, bottom).
We then tested the effects of PU.1 downregulation in
DNA methylation changes. We looked at both PU.1-tar-
get genes that become hypomethylated and hyperme-
thylated. In both cases, we observed that downregulation
of PU.1 impaired the acquisition of DNA methylation
changes, in contrast with the changes observed for con-
trol siRNA-treated MOs (Figure 5D). In the case of
TM7SF4, one of the key genes undergoing hypomethy-
lation, we did not detect an effect of PU.1 downregu-
lation on its DNA methylation dynamics (Additional file
10). However, this could perhaps be explained because
this gene undergoes changes before downregulation of
PU.1 by siRNA is effective, within day 1 (Additional file
10) and suggests the participation of other factors in this
process. At any rate, the observed effects only occurred
in PU.1 targets. It did not affect genes that are not
targeted by PU.1 (PLA2G4E, FSCN3). In the case of
PLA2G4E, PU.1-siRNA treatment did not impair the
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Figure 5 (See legend on next page.)
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Figure 5 PU.1 has a direct role in leading DNA methylation changes at their targets. (A) Scheme depicting the two regions of the SPI1
gene (PU.1) (exon 2 and 3′UTR) targeted by the two siRNAs used in this study. (B) Effects of siRNA experiments on PU.1 levels at 1, 2, 4, and
6 days as analyzed by qRT-pCR. (C) Effects of siRNA experiments on PU.1 levels at 1, 2, 4, and 6 days as analyzed by western blot (D) Effects of
PU.1 downregulation on expression and methylation of PU.1-target genes that become demethylated (ACP5, CTSK), genes that become
hypermethylated (CX3CR1, NR4A2) and non-pU.1 target genes, PLA2G4E, which becomes also overexpressed and demethylated, and FSCN3, which
is hypermethylated and does not undergo loss of methylation during osteoclastogenesis. (E) ChIP assays showing the effects of PU.1
downregulation in its recruitment, together with TET2 and DNMT3b binding to the same genes. Data were obtained at 0, 2, and 6 days after M-
CSF /RANL stimulation. To simplify the representation negative control assays with IgG for each time point have been substracted to the
experiments with each antibody. We have used the MYOD1 promoter as a negative control (data without substracting the background is
presented in Additional file 10). The experiment was performed with three biological triplicates but only one experiment is shown. Error bars
correspond to technical replicates. Some of them are smaller than the data point icon. T-student test was performed: * corresponds to P value
<0.05; ** means P value <0.01; *** means P value <0.001.
de la Rica et al. Genome Biology 2013, 14:R99 Page 13 of 21
http://genomebiology.com/2013/14/9/R99experiment. For FSCN3, we observed no loss of methyla-
tion in any case (Figure 5D).
Finally, we compared the effect of PU.1 downregu-
lation in the recruitment of DNMT3b and TET2 to
hyper- and hypomethylated promoters (Figure 5E and
Additional file 10). As expected, we observed that PU.1
dowregulation resulted in a decrease of the levels of
PU.1 associated with the promoters of both hypo- and
hypermethylated genes. Most importantly, it also re-
duced the association of DNMT3b and TET2 reinforcing
the notion of the role of these factors and their associ-
ation with PU.1 in the DNA methylation changes occur-
ring at these CpG sites (Figure 5E). The time course
analysis (at 2 and 6 days) of these results also revealed a
complex dynamics for the PU.1, TET2, and DNMT3b
interactions with their target genes, particularly in the
case of hypermethylated genes. It is possible that per-
turbation of PU.1 levels could be compensated by add-
itional factors that participate in the acquisition of DNA
methylation changes of these genes. These aspects will
need to be further investigated.
Discussion
Our results provide evidence of the participation of tran-
scription factors, focusing on PU.1, in determining
changes in DNA methylation during monocyte-to-osteo-
clast differentiation. First, a detailed analysis of the
sequences undergoing DNA methylation changes pro-
duced evidences of the participation of several transcrip-
tion factors, given the specific over-representation of
certain motifs in hypo- and hypermethylated genes. This
initial analysis was validated in several candidate genes
and using ChIPseq data for human primary monocytes
[1]. Second, further analyses on one these candidate
transcription factors, PU.1, and manipulation of its levels
revealed a novel role for this factor in mediating DNA
methylation changes during osteoclastogenesis, by direct
binding of both DNMT3B and TET2.
In general, DNA methylation changes in differenti-
ation or any other dynamic process are of interest for
two reasons: (1) these changes are generally associatedwith gene expression changes, particularly when associ-
ated with promoters or gene bodies, and reveal aspects
intrinsic to identity and function of the corresponding
cell types; (2) they can be considered as epigenetic foot-
prints that, despite not necessarily being associated with
an expression or organizational change, reveal a change
in the milieu of a particular CpG and therefore can be
used to trace the participation of specific transcription
factors or other nuclear elements in that environment/
neighborhood. This information can then be used to re-
construct cell signaling events, transcription factors in-
volved and mechanisms participating in differentiation.
In this sense, our data show that DNA methylation
changes are involved in the differentiation dynamics and
stabilization of the OC phenotype since they are con-
comitant with, or even precede, expression changes.
These data are closely correlated with gene expression
changes, and a majority of genes that undergo
hypomethylation or hypermethylation at their promoters
or gene bodies also experience a change in expression,
although the relationship varies between different gene
sets. Finally, gene ontology analysis reveals that all rele-
vant functional categories and the majority of key genes
for differentiation or the activity of functional OCs
undergo DNA methylation changes and that genes
within all relevant functional categories undergo DNA
methylation changes.
Our study suggests that both hypomethylation and
hypermethylation events are equally important. Hypo-
methylation events, in many cases associated with gene
activation, affect genes that are specific to this differenti-
ation process or are related with the function of differen-
tiated OCs. In contrast, the identity of genes affected by
hypermethylation events is less closely correlated with
OC function, given that most of them are related with
gene repression. In fact, we found that hypermethylation
affects genes that are specific to other cellular types.
Given that osteoclastogenesis involves cell fusion and
the generation of highly polyploid cells, we had specu-
lated whether the existence of redundant copies of gen-
etic material could lead to massive gene repression, and
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does not seem to be predominant over hypomethylation.
The two activities are very specific to particular gene
sets and there are no indications of changes in repetitive
elements.
A number of transcription factors are essential for OC
formation. Some of these factors are involved in various
differentiation processes. Among these, PU.1, c-Fos,
NF-kB, and other factors are essential for osteoclas-
togenesis. In fact, NF-kB- and PU.1-deficient mice
show a macrophage differentiation failure, and osteo-
clastogenesis is inhibited at an early stage of differen-
tiation. c-Fos is a component of the dimeric TF AP-1,
which also includes FosB, Fra-1, Fra-2, and Jun pro-
teins such as c-Jun, JunB, and JunD. Other key fac-
tors involved in OC differentiation include C/EBPα
[47] and Bach1 [48]. Osteoclastogenesis also depends
on the activity of more specific transcription factors
like NFATc1 and MITF. Interestingly, the analysis of
the presence of transcription factor binding sites in
sequences that undergo DNA methylation changes
shows a significant enrichment in binding motifs of
transcription factors that are key in OC differenti-
ation, some of which we have validated for a selec-
tion of putative target genes.
One of the most interesting factors in this process is
the ETS factor PU.1. In fact, PU.1 is the earliest mol-
ecule known to influence the differentiation and com-
mitment of precursor myeloid cells to the OC lineage.
PU.1 functions in concert with other transcription fac-
tors, including c-Myb, C/EBPα, cJun, and others, to acti-
vate osteoclast-specific genes.
Our results reveal two hitherto undescribed roles
for PU.1 in the context of monocyte-to-OC differenti-
ation. First, we have identified the association of PU.1
with genes that become repressed through hyperme-
thylation and describe its direct interaction with
DNMT3b in the context of osteoclastogenesis. Sec-
ond, we identify a novel interaction between PU.1
and TET2 and their association with genes that be-
come demethylated. Our study shows that PU.1 may
act as a dual adaptor during osteoclastogenesis, in the
directions of hypomethylation and hypermethylation.
This is compatible with previous data on genome
wide DNA methylation profiling comparing cell types
across the hematopietic differentiation system where
an over-representation of ETS transcription factor
binding sites was found [2]. In monocyte-to-osteoclast
differentiation, PU.1 is best known for its role in the
activation of osteoclast-specific genes. However, stud-
ies in other models have previously shown that PU.1
can participate in the repression of genes in concert
with elements of the epigenetic machinery. For
instance, PU.1 is known to generate a repressivechromatin structure characterized by H3K9me3 in
myeloid and erythroid differentiation [49]. Also, PU.1
has been shown to act in concert with MITF to re-
cruit co-repressors to osteoclast-specific in committed
myeloid precursors capable of forming either macro-
phages or OC [50]. Moreover, previous studies have
shown that PU.1 can form a complex with DNMT3a
and DNMT3b [46]. However, this is the first report
where the association between PU.1 and DNMTs in
association with gene repression is shown in this
context.
Moreover, our findings constitute the first report
where the binding of PU.1 to TET2 has been described.
Several recent reports have pointed at TET2-mediated
hydroxylation of 5-methylcytosine as an intermediate
step towards demethylation [51] and our data show
changes in 5hmC at genes that become demethylated in
osteoclastogenesis, reinforcing the possibility that
PU.1-mediated recruitment of TET2 is leading to
5hmC-mediated demethylation. However the detailed
mechanisms that couple hydroxylation of 5mC and
demethylation are still objects of debate.
The manipulation of PU.1 levels by using siRNAs has
shown that PU.1 has a direct role in recruiting DNMT3b
and TET2 to its target promoters, as well as showing
how impaired association of PU.1 results in defective ac-
quisition of DNA methylation changes in both directions
as well as reduced effect on gene expression changes.
Therefore, our data reveal a novel role of PU.1 as a dual
adaptor with the ability to bind both epigenetically
repressive and epigenetically activating events and
targeting DNA methylation changes in both directions
(Figure 6). The incomplete impairment of DNA methy-
lation and expression changes, as well as partial loss of
Tet2 and DNMT3b following PU.1 knock-down indi-
cates that additional transcription factors are also par-
ticipating in this process. In future studies, it will also be
interesting to identify the mechanisms that operate in
the specific recruitment of PU.1-TET2 to genes that
become demethylated, and to determine how PU.1-
DNMT3b is recruited to genes that become hyperme-
thylated. It is likely that specific transcription factors
play a role, and specific post-translational modifications
in PU.1 may participate in the coupling of its associated
complexes to specific factors. In this context, Ser phos-
phorylation of PU.1 has already been shown to play a
role in its recruitment to promoters [52] and could also
participate in discriminating interaction with epigenetic
modifiers.
Our study has allowed us to identify key DNA methy-
lation changes during OC differentiation and has re-
vealed an implication of PU.1 in the acquisition of DNA
methylation and expression changes as well as identify-


















Figure 6 Model showing a simplified diagram proposing the recruitment of TET2 and DNMT3b by PU.1 to its target genes that
become hypo- or hypermethylated, respectively, during osteoclastogenesis. Genes that become hypomethylated exchange PU.1-DNMT3b
by PU.1-TET2 (although whether pre-existing subpopulations of these associations may exist or, alternatively, post-translational or another
mechanisms may mediate exchange of TET2 and DNMT3b; this is not elucidated at present). TDG is likely to mediate conversion of 5hmC/5fmC/
5caC to demethylated cytosine. Hypermethylated genes experience an increase in the binding of DNMT3b as differentiation to OCs is triggered.
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Our study of the DNA methylation changes in monocyte-
to-osteoclast differentiation reveals the occurrence of both
hypomethylation and hypermethylation changes. These
changes occur in the virtual absence of DNA replication
suggesting the participation of active mechanisms, particu-
larly relevant for hypomethylation events, for which the
mechanisms are still subject of debate. Also, when com-
paring the dynamics of DNA methylation and expression
changes, hypomethylation occurs concomitant or even
earlier than expression changes. In contrast, for the major-
ity of genes becoming hypermethylated, hypermethylation
follows expression changes. Hypomethylation takes place
in relevant functional categories related with OC differen-
tiation and most of the genes that are necessary for OC
function undergo hypomethylation including ACP5,
CTSK, and TM7SF4 among others. The analysis of over-
representation of transcription factor binding motifs re-
veals the enrichment of specific motifs for hypomethylated
and hypermethylated genes. Among these, PU.1 and other
ETS-related binding motifs are highly enriched in both
hypomethylated and hypermethylated genes. We have
demonstrated that PU.1 is bound to both hypo- and
hypermethylated promoters and that it is able to recruit
both DNMT3b and TET2. Most importantly, downre-
gulation of PU.1 with siRNAs not only shows a reduction
in the recruitment of these two enzymes to PU.1 target
genes but also results in a specific reduction in the acqui-
sition of DNA methylation and expression changes at
those targets. Our results demonstrate a key role of PU.1
in driving DNA methylation changes during OC
differentiation.Materials and methods
Differentiation of OCs from peripheral blood
mononuclear cells
Human samples (blood) used in this study came from
anonymous blood donors and were obtained from the
Catalan Blood and Tissue Bank (Banc de Sang i Teixits)
in Barcelona as thrombocyte concentrates (buffy coats).
The anonymous blood donors received oral and written
information about the possibility that their blood would
be used for research purposes, and any questions that
arose were then answered. Prior to obtaining the first
blood sample the donors signed a consent form at the
Banc de Teixits. The Banc de Teixits follows the princi-
ples set out in the WMA Declaration of Helsinki. The
blood was carefully layered on a Ficoll-Paque gradient
(Amersham, Buckinghamshire, UK) and centrifuged at
2,000 rpm for 30 min without braking. After centrifuga-
tion, peripheral blood mononuclear cells (PBMCs), in
the interface between the plasma and the Ficoll-Paque
gradient, were collected and washed twice with ice-cold
PBS, followed by centrifugation at 2,000 rpm for 5 min.
Pure CD14+ cells were isolated from PBMCs using posi-
tive selection with MACS magnetic CD14 antibody
(Miltenyi Biotec). Cells were then resuspended in α-
minimal essential medium (α-MEM, Glutamax no nucle-
osides) (Invitrogen, Carlsbad, CA, USA) containing 10%
fetal bovine serum, 100 units/mL penicillin, 100 μg/mL
streptomycin and antimycotic and supplemented with
25 ng/mL human M-CSF and 50 ng/mL hRANKL sol-
uble (PeproTech EC, London, UK). Depending on the
amount needed, cells were seeded at a density of 3 · 105
cells/well in 96-well plates, 5 · 106 cells/well in 6-well
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21 days (unless otherwise noted); medium and cytokines
were changed twice a week. The presence of OCs was
checked by tartrate-resistant acid phosphatase (TRAP)
staining using the Leukocyte Acid Phosphatase Assay
Kit (Sigma-Aldrich) according to the manufacturer’s in-
structions. A phalloidin/DAPI stain allowed us to con-
firm that the populations were highly enriched in
multinuclear cells, some of them containing more than
40 nuclei. We used several methods to determine that
on day 21 almost 85% of the nuclei detected were ‘osteo-
clastic nuclei’ (in polykaryons, nuclei and not cells were
quantified). OCs (TRAP-positive cells with more than
three nuclei) were also analyzed at the mRNA level:
upregulation of key OC markers (TRAP/ACP5, CA2,
MMP9, and CTSK) and the downregulation of the MO
marker CX3CR1 were confirmed.
Treatment of MOs with 5-aza-2-deoxycytidine
In some cases we performed monocyte-to-osteoclast dif-
ferentiation experiments in the presence of different
subtoxic concentrations of the DNA replication-coupled
demethylating drug 5-aza-2-deoxycytidine (at 50 nM,
500 mM) for 72 h.
Visualization of OCs with phalloidin and DAPI staining
PBMCs or pure isolated CD14+ cells were seeded and
cultured in glass Lab-Tek Chamber Slides (Thermo
Fisher Scientific) for 21 days in the presence of hM-CSF
and hRANKL. OCs were then washed twice with PBS
and fixed (3.7% paraformaldehyde, 15 min). Cells were
permeabilized with 0.1% (V/V) Triton X-100 for 5 min
and stained for F-actin with 5 U/mL Alexa Fluor® 647-
Phalloidin (Invitrogen). Cells were then mounted
in Mowiol-DAPI mounting medium. Cultures were
visualized by CLSM (Leica TCP SP2 AOBS confocal
microscope).
DNA methylation profiling using universal bead arrays
Infinium HumanMethylation450 BeadChips (Illumina,
Inc.) were used to analyze DNA methylation. This array
allows interrogating >485,000 methylation sites per sam-
ple at single-nucleotide resolution, covering 99% of
RefSeq genes, with an average of 17 CpG sites per gene
region distributed across the promoter, 5′UTR, first
exon, gene body and 3′UTR. It covers 96% of CpG
islands, with additional coverage in CpG island shores
and the regions flanking them. DNA samples were bisul-
fite converted using the EZ DNA methylation kit (Zymo
Research, Orange, CA, USA). After bisulfite treatment,
the remaining assay steps were performed following the
specifications and using the reagents supplied and
recommended by the manufacturer. The array was hy-
bridized using a temperature gradient program, andarrays were imaged using a BeadArray Reader (Illumina,
Inc.). The image processing and intensity data extraction
software and procedures were those previously described
[53]. Each methylation data point is obtained from a
combination of the Cy3 and Cy5 fluorescent intensities
from the M (methylated) and U (unmethylated) alleles.
Background intensity computed from a set of negative
controls was subtracted from each data point. For repre-
sentation and further analysis we used both Beta values
and M values. The Beta-value is the ratio of the methyl-
ated probe intensity and the overall intensity (sum of
methylated and unmethylated probe intensities). The M
value is calculated as the log2 ratio of the intensities of
methylated probe versus unmethylated probe. The Beta
value ranges from 0 to 1 and is more intuitive and was
used in heatmaps and in comparisons with DNA
methylation percentages from bisulfite pyrosequencing
experiments, however for statistics purposes it is more
adequate the use of M values [54].
Detection of differentially methylated CpGs
The approach to select differentially methylated CpGs
was implemented in R [55], a well-known language in
statistical computing. In order to process Illumina
Infinium HumanMethylation450 methylation data, we
used the methods supplied in limma [56], genefilter, and
lumi [57] packages from Bioconductor repository. Previ-
ous to statistical analysis, a pre-process stage is applied,
the main steps are: (1) color balance adjustment, that is,
normalization between two color channels; (2) perfor-
ming quantile normalization based on color balance
adjusted data; and (3) variance filtering by IQR (inter-
quartile range) using 0.50 for threshold value.
Subsequently, for statistical analysis, eBayes moderated
t-statistics test was carried out from limma package [56].
Specifically, a paired limma was performed as designed
in IMA package [58]. To choose significant differences in
methylated CpGs several criteria have been proposed. In
this study, we considered a probe as differentially methyl-
ated if: (1) it has a fold-change >2 for hypermethylated
and <0.5 hypomethylated; and (2) the statistical test was
significant (P value <0.01 and FDR <0.05).
Identification of genomic clusters of differentially
methylated CpGs
A clustering method was applied to the differenced
methylated CpGs from charm package [59]. We re-
implemented the code to invoke the main clustering
function using genomic CpG localization: identify differ-
entially methylated regions (DMRs) by grouping differ-
entially methylated probes (DMPs). The maximum
allowable gap between probe positions for probes to be
clustered into the same region was set to 500 bp. It has
been shown that in many cases methylation changes are
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for instance at shores close to transcription starting sites.
We considered that DMR are more robust signals than
DMPs. In this analysis, the considered list of CpGs
attains a P value <0.01 and FDR <0.05.
Bisulfite sequencing and pyrosequencing
We used bisulfite pyrosequencing to validate CpG
methylation changes resulting from the analysis with the
Infinium HumanMethylation450 BeadChips. Bisulfite
modification of genomic DNA isolated from MOs, OCs,
and samples from time course or PU.1-knockdown ex-
periments was carried out as described by Herman et al.
[60]. A total of 2 μL of the converted DNA (correspond-
ing to approximately 20–30 ng) were then used as a
template in each subsequent PCR. Primers for PCR
amplification and sequencing were designed with the
PyroMark® Assay Design 2.0 software (Qiagen). PCRs
were performed with the HotStart Taq DNA polymerase
PCR kit (Qiagen), and the success of amplification was
assessed by agarose gel electrophoresis. PCR products
were pyrosequenced with the Pyromark™ Q24 system
(Qiagen). In the case of repetitive elements (Sat2, D4Z4,
NBL2, 18S rRNA, and 28 rRNA) we performed standard
bisulfite sequencing of a minimum of 10 clones. Results
from bisulfite pyrosequencing and sequencing of mul-
tiple clones are presented as a percentage of methyla-
tion. All primer sequences are listed in Additional file
11. Raw data for bisulfite sequencing of all samples is
presented in Additional file 4.
Gene expression data analysis and comparison of DNA
expression data versus DNA methylation data
In order to compare expression data versus methylation
data, we used CD14+ and OC expression data from
ArrayExpress database [61] under the accession name
(E-MEXP-2019) from a previous publication [32].
Affymetrix GeneChip Human Genome U133 Plus 2.0
expression data was processed using limma [56] and affy
[62] packages from bioconductor. The preprocessing
stage is divided into three major steps: (1) background
correction; (2) normalization; and (3) reporter summa-
rization. Here, the expresso function in the affy package
was chosen for preprocessing. Thus, the RMA method
[63] was applied for background correction. Then, a
quantile normalization was performed. In addition, we
introduced a specific step for PM (perfect match probes)
adjustment, utilizing the PM-only model based expres-
sion index (option ‘pmonly’). And finally, for summa-
rization step, the median polish method was taken. Next,
as previously in the methylation analysis, a variance
filtering by IQR using 0.50 for threshold value was
executed. After preprocessing, a statistical analysis was
applied, using eBayes moderated t-statistics test fromlimma package. Subsequently, expression genes mat-
ching to methylated genes were studied. Genes differen-
tially expressed between MOs and Mo-OCs groups were
selected with a criteria of P value <0.01 and FDR <0.05
as calculated by Benjamini-Hochberg and a fold-change
of expression >2 or <0.5. Validation of expression data
was performed by quantitative RT-PCR. All primer se-
quences are listed in Additional file 11.
Gene ontology analysis
Gene ontology (GO) was analyzed with the FatiGO tool
[64], which uses Fisher’s exact test to detect significant
over-representation of GO terms in one of the sets (list
of selected genes) with respect to the other (the rest of
the genome). Multiple test correction to account for the
multiple hypotheses tested (one for each GO term) was
applied to reduce false-positive results. GO terms with
adjusted values of P <0.05 were considered significant.
Analysis of transcription factor binding
We used the STORM algorithm [65] to identify potential
over-representation of transcription factor motifs in the
500-bp region around the center of the hypomethylated/
hypermethylated CpG sites (as well as for all other
CpGs-containing probes contained in the array) assum-
ing cutoff values of P = 0.00002 (for hypo-/hyperme-
thylated probes) and 0.00001 (for all other probes), using
position frequency matrices (PFMs) from the TRANS
FAC database (Professional version, release 2009.4) [66].
Enrichment analysis of predicted TF in the probes of sig-
nificant hypomethylated probes (n = 421) was conducted
using GiTools [67,68]. We calculated two-tailed prob-
abilities, and a final adjusted FDR P value (with 0.25 cut-
off ) was considered statistically significant.
We downloaded PU.1 ChIPseq data for CD14+ MOs
generated by Michael Rehli’s laboratory [1] from the
Gene Expression Omnibus (GSE31621). The genomic
locations of the calculated peaks were mapped to
GRCh37.p10 human alignment obtained from Biomart
[69], by using bedtools (intersect function) in order to
obtain the PU.1 occupied genes. To determine whether
a given CpG (from the Illumina bead array) was positive
for PU.1 binding, we used the same 500-bp window used
for TRANSFAC analysis.
Graphics and heatmaps
All graphs were created using Prism5 Graphpad.
Heatmaps were generated from the expression or methy-
lation data using the Genesis program (Graz University
of Technology) [70].
BrdU proliferation assays
BrdU was used at a final concentration of 300 μm, as
previously described. On the days specified, BrdU
de la Rica et al. Genome Biology 2013, 14:R99 Page 18 of 21
http://genomebiology.com/2013/14/9/R99pulsing solution was added to each well for 2 to 4 days.
For confocal microscopy of monocyte-to-osteoclast dif-
ferentiation samples, CD14+ cells were seeded on
Millicell EZ 8-well glass slides (Millipore) and cultured
in differentiation media. At different times BrdU was
added to the medium and after 2 to 4 days cells were
fixed (4% paraformaldehyde, 30 min, RT), permeabilized
(PBS-BSA-Triton X-100 0.8% (PBT), 10 min, RT) and
treated with HCl 2 N for 30 min. After DNA opening,
HCl was neutralized by two 5-min washes with NaBo
(0.1 M, pH 8.5) and two 5-min washes with PBT. Cells
were incubated with anti-BrdU antibody (18 h at 4°C,
1:1,000 dilution) and an anti-mouse Alexa-568 conju-
gated antibody was added to visualize the BrdU-positive
nuclei. A phalloidin incubation step and Mowiol-DAPI
mounting media were used.
Transfection of primary human MOs
We used two different Silencer® select pre-designed
siRNAs against human PU.1 (one targeting exon 2 and
another targeting the 3′UTR) and a Silencer® select
negative control to perform PU.1 knockdown experi-
ments in peripheral blood MOs. We used Lipofectamine
RNAiMAX Transfection Reagent (Invitrogen) for effi-
cient siRNA transfection. mRNA and protein levels were
examined by quantitative RT-PCR and western blot at 1,
2, 4, and 6 days after siRNA transfection. In this case
MO samples were prepared by incubating PBMCs in
plates in α-MEM without serum for 30 min and washing
out the unattached cells. Under these conditions over
80% are MOs. This alternative protocol was used for in-
creased viability following transfection. These experi-
ments were performed with three biological replicates.
Chromatin immunoprecipitation (ChIP) assays and
immunoprecipitation experiments
Immunoprecipitation was performed by standard proce-
dures in CD14+ cells at 0, 2, and 4 days after treatment
with M-CSF and RANKL. Cell extracts were prepared in
50 mM Tris–HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl,
1% Triton-X-100, and protease cocktail inhibitors
(Complete, Roche Molecular Biochemicals). Cellular
extracts and samples from immunoprecipitation experi-
ments were electrophoresed and western blotted follow-
ing standard procedures.
For chromatin immunoprecipitation (ChIP) assays,
CD14+ at 0, 2, and 4 days after treatment with M-CSF
and RANKL were cross-linked with 1% formaldehyde
and subjected to immunoprecipitation after sonication.
ChIP experiments were performed as described [44].
Analysis was performed by real-time quantitative PCR.
Data are represented as the ratio of the bound fraction
over the input for each specific factor. We used a mouse
monoclonal antibody against the TET2 N-t for ChIPsand a rabbit polyclonal antibody against TET2 for
western blot. For DNMT3b we used a rabbit polyclonal
against amino acids 1–230 of human DNMT3b (sc-
20704, Santa Cruz Biotechnology). We also used a rabbit
polyclonal against the C-t of PU.1 (sc-352, Santa Cruz
Biotechnology), a rabbit polyclonal against the N-t of
c-Fos (sc-52, Santa Cruz Biotechnology) and a rabbit
polyclonal against the C-t of NF-kB p65 (sc-372, Santa
Cruz Biotechnology). IgG was used as a negative control.
Primer sequences were designed to contain either pre-
dicted or known TF binding (from TRANSFAC or
ChIPseq data) as close as possible from the CpG under-
going methylation changes. Primer sequences are shown
in Additional file 11. These experiments were performed
with three biological replicates.5hmC detection
5hmC was analyzed using the Quest 5hmC Detection
system (Zymo). Genomic DNA was treated with a spe-
cific 5hmC glucosyltransferase (GT) or left untreated
(No GT, 0% 5hmC). DNA was then digested with MspI
(100U) at 37°C overnight, followed by column purifica-
tion. The MspI-resistant fraction (bearing the glucosile
group, and therefore the original 5hmC) was quantitated
by qPCR using primers designed around at least one MspI
site (CCGG), and normalized to the amplification of the
same region in the original DNA input. The amplification
obtained in the untreated (no GT, MspI sensible) was then
substracted to the samples in order to calculate the level
of 0% 5hmC. The resulting values were the percentage of
5hmC present in each of the samples. Primer sequences
are shown in Additional file 11.Amplification of unmethylated Alus
This method, aiming at the amplification of unmethylated
Alus (AUMA), was performed as described [31,39]. Prod-
ucts were resolved on denaturing sequencing gels. Bands
were visualized by silver staining the gels. AUMA finger-
prints were visually checked for methylation differences
between bands in different samples.Additional files
Additional file 1: M-CSF and RANKL-induced monocyte-to-
osteoclast differentiation. (A) Visualization of the formation of the actin
ring and the generation of polykaryons in monocyte (MO) to osteoclast
(OC) differentiation with phalloidin and DAPI staining. (B) TRAP (Tartrate
resistant acid phosphatase-OC marker) staining in MO and OC
preparations, showing this activity only in OCs. Determination of the
typical percentage of osteoclastic nuclei present in the preparations used
for the experiments; over 84% efficiency was achieved at 21 days. (C)
Upregulation of OC specific markers (CA2, CTSK, MMP9, ACP5) was
checked by qPCR; downregulation of a monocyte specific gene (CX3CR1)
was also monitored.
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genes during monocyte to osteoclast differentiation (FC <0.5
(hypomethylated, sheet 1) or FC >2.
Additional file 3: (A) Scatterplots showing DNA methylation
profiles of matching MO/OC pairs. Genes with significant differences
(FC >2, FDR <0.05) in averaged results from three samples are
highlighted in red (hypermethylated) or blue (hypomethylated). Three
panels corresponding for each of the three individual comparisons of
MO/OC pairs (D1, D2, and D3) are shown. (B) Bisulfite sequencing
analysis of repetitive sequences performed on monocytes (day 0) and
osteoclasts (day 21) from three different donors (donor A, donor B, and
donor C), showing no relevant differences in the DNA methylation levels.
(C) AUMA (amplification of unmethylated Alus) analysis of two
independent monocyte-to-osteoclast differentiation experiments. Graphs
correspond to the scanned intensities of the bands obtained with two
different sets of primers. No significant differences are observed.
Additional file 4: Individual raw data corresponding to bisulfite
pyrosequencing and standard bisulfite sequencing of individual MO
and OC samples (Figure 1E), time course methylation data
(Figure 2D, E) and PU.1 siRNA experiments (Figure 5D). Data are
presented as supplied by PyroMark® Assay Design Software 2.0 for
PyroMark Q96 MD (Qiagen), which automatically generates methylation
percentages in a datasheet format.
Additional file 5: Clusters of consecutive CpGs hypomethylated (−)
or hypermethylated (+) in OC vs. MO.
Additional file 6: Differentially expressed genes between Mos, OC
samples at 5 days and OC samples at 20 days after RANKL/M-CSF
stimulation (FC >2, FC <0.5; FDR <0.05).
Additional file 7: List of genes with an inverse relationship
between DNA methylation and expression change (FC <0.5 or
FC >2; FDR <0.05 for both DNA methylation and expression data).
Additional file 8: (A) Scheme showing the BrdU pulses added to
monocytes differentiating into osteoclasts. (B) Representative
immunofluorescence images at the selected time points showing BrdU
positive cells. (C) Representation of the time scale where DNA
demethylation occurs during osteoclast differentiation, together with the
cell division observed at later time points.
Additional file 9: Osteoclast differentiation scheme showing
transcription factors that are known to be involved in monocyte-
to-osteoclast differentiation. We have in red or blue the presence of
binding motifs for those factors (according to TRANSFAC analysis) among
the sequences surrounding the CpGs that become hypo- or
hypermethylated. Those arising from our analysis are highlighted in red
and blue (associated with hypermethylation and hypomethylation,
respectively).
Additional file 10: (A) ChIP assays showing the effects of PU.1
downregulation in its recruitment, together with TET2 and DNMT3b
binding to the same genes. Data were obtained at 0, 2, and 6 days
after M-CSF/RANL stimulation. (B) We have used the MYOD1 promoter as
a negative control. (C) Effects of PU.1 downregulation on expression and
methylation of PU.1-target gene TM7SF4.
Additional file 11: List of primers.Abbreviations
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